Glenmark wins Russian Health Ministry nod for allergic rhinitis drug Montlezir

Glenmark Pharma's allergic rhinitis drug Montlezir is expected to be available in the Russian market in Q3 FY 2019‐20.

Mumbai: Glenmark Pharmaceuticals Ltd., (Glenmark Pharma)today announced that it has received approval from the Ministry of Healthcare, Russia to market Montlezir (Levocetirizine Dihydrochloride 5mg + Montelukast Sodium 10mg) film‐coated tablets as a prescription product for the treatment of seasonal and perennial allergic rhinitis in patients above 15 years of age.

Montlezir is expected to be available in the Russian market in Q3 FY 2019‐20.

Commenting on the approval, Csaba Kantor, Senior Vice President and Head ‐ Asia, Russia & CIS region, Glenmark Pharmaceuticals, said, “Glenmark has built strong capabilities in the area of respiratory and is among the leading players in this therapy area across several markets globally. Russia is one of the key markets for us and we are consistently looking to expand our product portfolio. We believe that approval for Montlezir will help enhance our presence in this segment.”

Also Read: Glenmark Pharma to raise Rs 1413 crore via debt securities

“Allergic rhinitis affects a significant number of people in Russia, and we already have a number of products in our portfolio for the treatment of this condition. The approval to market Montlezir will further strengthen our company’s position in this segment and we are delighted to be able to bring new products to the market for patients suffering from this condition,” said Oxana Pozdnyakova, Vice President and Business Head – Russia, Glenmark Pharmaceuticals.

According to IQVIA, Glenmark ranked 47th in the retail segment of the Russian pharmaceutical market as of MAT July 2019. In the respiratory space, Glenmark continues to secure a strong position and ranked 4th amongst the companies present in the expectorants market in Russia as of MAT July 2019. The company is ranked 10th in the retail dermatology market in the country.

Also Read: Glenmark bags USFDA orphan drug status for antibody GBR 1342 to treat multiple myeloma